US Regulatory Review Update: Tolebrutinib for Non-Relapsing Secondary Progressive MS
The U.S. Food and Drug Administration (FDA) has extended the target action date for its review of Sanofi’s new drug application (NDA) for tolebrutinib by three months, now set for…
Read More...
Read More...
